
ABSTRACT Disinfection of drinking water is essential for preventing waterborne infectious diseases. However, disinfectants can react with natural organic matter, bromide, iodide, ammonia, and other precursors to form disinfection byproducts (DBPs). Because DBPs are widely detected in drinking‐water systems and may differ substantially in toxicity, persistence, and exposure potential, their possible contribution to cancer remains an important public‐health concern. This systematic review summarizes epidemiological and experimental evidence concerning the relationship between drinking‐water DBPs and cancer. Literature searches were conducted in PubMed, Web of Science, and Scopus using predefined combinations of terms related to DBPs, drinking‐water exposure, cancer, epidemiology, genotoxicity, oxidative stress, and carcinogenic mechanisms. Eligible studies included population‐based epidemiological studies, toxicological and mechanistic studies, systematic reviews, and meta‐analyses. The evidence was synthesized narratively because of substantial heterogeneity in exposure metrics, study populations, cancer outcomes, and effect measures. The methodological limitations of the included studies were considered with particular attention to exposure misclassification, residual confounding, selection bias, outcome ascertainment, and publication bias. Trihalomethanes (THMs) and haloacetic acids (HAAs) were the most frequently investigated DBP groups and therefore provided the principal epidemiological evidence in this review. However, the review also considered emerging nitrogen‐containing, brominated, iodinated, aromatic, alicyclic, and inorganic DBPs. For these emerging compounds, evidence was evaluated primarily on the basis of occurrence, toxicological potency, genotoxicity, and mechanistic plausibility. The most consistent epidemiological evidence concerned bladder cancer, for which several case–control and cohort studies reported positive associations with long‐term exposure to total THMs or specific THM constituents. Associations with colorectal, kidney, ovarian, and selected hematological cancers were less consistent and should be considered suggestive rather than conclusive. Evidence for causal interpretation was limited by difficulties in reconstructing long‐term individual exposure, insufficient characterization of inhalation and dermal exposure, regional variability in DBP composition, and incomplete adjustment for tobacco smoking, occupational exposures, diet, socioeconomic status, and other potential confounders. Experimental studies indicate that some DBPs, particularly brominated and nitrogen‐containing compounds, can induce oxidative stress, DNA adduct formation, DNA strand breaks, chromosomal damage, altered DNA methylation, histone modification, mitochondrial dysfunction, inflammatory signaling, and dysregulation of cell‐cycle and apoptosis pathways. These mechanisms provide biological plausibility for some epidemiological observations but do not establish that all DBPs or DBP mixtures cause cancer in humans. Overall, the evidence supports a relatively stable association between long‐term drinking‐water DBP exposure and bladder cancer, whereas evidence for other cancer sites remains limited or inconsistent. Future studies should prioritize prospective cohort designs, improved individual‐level exposure assessment, biomonitoring, mixture‐based analysis, evaluation of multiple exposure routes, preregistered protocols, and transparent risk‐of‐bias assessment. Regulatory frameworks should progressively incorporate unregulated and emerging DBPs while maintaining adequate microbial protection. The greater emphasis on THMs and HAAs reflects the availability of epidemiological evidence rather than a conclusion that these compounds are more toxic than all emerging DBPs. Emerging DBPs, particularly N‐nitrosamines, haloacetonitriles, iodinated DBPs, halogenated benzoquinones, and halofuranones, warrant further occurrence monitoring, toxicological evaluation, and mixture‐based risk assessment.
ABSTRACT TGx‐DDI and TGx‐HDACi are transcriptomic biomarkers used to classify chemicals based on gene expression profiles indicative of DNA damage‐inducing (DDI) or histone deacetylase inhibition (HDACi) mechanisms. Both employ nearest shrunken centroid (NSC) analysis, hierarchical cluster analysis (HCA), and principal component analysis (PCA). While NSC allows for inconclusive calls when class membership probability is low, PCA has historically lacked an objectively defined inconclusive region. This study establishes a distance‐based probabilistic threshold for PCA, using TGx‐DDI as the primary example, to define a quantitative inconclusive zone along the first principal component (PC1). Samples with ambiguous PC1 values are objectively classified as inconclusive, preventing overconfident misclassifications of weak transcriptomic signals. For TGx‐HDACi, the inconclusive region is narrower but widens substantially with fewer biomarker genes, highlighting increased uncertainty with limited transcriptomic data. Implementing these thresholds enhances the reliability of TGx‐DDI assessments, transparently aligning PCA with NSC to inform regulatory decision‐making.
Charged particles like iron-56 ions impose health risks in long-term manned space exploration. This study was designed to define the impact of Trp53 status upon the manifestation of mutations in the hypoxanthine-guanine phosphoribosyltransferase (Hprt) gene in splenic T-cells following exposure of Trp53 wild-type, hemizygous, and nullizygous lacZ transgenic mice to 1 Gy 56Fe particles. In male and female mice necropsied at 2, 4, and 8 weeks postexposure, Hprt mutant frequencies in splenic T-cells (measured via the Hprt mutation cloning assay) increased significantly over time to peak at 4 weeks postexposure before decreasing to lower but still elevated levels. Mutagenic potency estimates based upon the change in mutant frequency over time in exposed versus respective control groups showed that the total mutagenic response depended upon the Trp53 genetic status, with the mutagenic burden of 1 Gy being threefold and 5.3-fold greater in Trp53 +/- and Trp53 -/- mice, respectively, compared to Trp53 +/+ mice.
ABSTRACT Exposure to diesel exhaust (DE) significantly contributes to air pollution. DE dysregulates miRNA expression, miRNA‐target interactions promoting tissue remodeling and lung inflammation. In the present study, C57BL/6 mice were divided into two groups: one was given DE for 30 min/day, 5 days/week, for 8 weeks whereas the control group was given filtered air. BALF and lungs were collected for cytokine analysis. MiRNA expression was analyzed in lungs using microarrays. qRT‐PCR and western blotting validated miRNAs and target genes. Functional impacts of miRNA‐target gene interaction were studied using in vitro and in vivo models. DE exposure downregulated miR‐133b‐3p (> 2‐fold, p < 0.05) prompting investigation into downstream effects. In silico analysis identified 371 potential targets of miR‐133b‐3p, with Hippo signaling as one of the most enriched pathways wherein CTGF, FGF1 , and TCF7 genes shared a common predicted binding site for miR‐133b‐3p. Functional validation using A549 cells showed transfection with miR‐133b‐3p mimic reduces CTGF expression at both mRNA ( p = 0.0054) and protein ( p = 0.0001) levels, while inhibition of miR‐133b‐3p restored CTGF expression, confirming it as a direct target. In vivo, DE exposure increased CTGF mRNA & protein expression whereas decreased P‐ YAP/YAP ratio was consistent with Hippo pathway dysregulation and co‐occurred with miR‐133b‐3p downregulation. DE exposure also increased pro‐inflammatory cytokines (IL‐18, IL‐1β, GM‐CSF) in BALF, indicating increased inflammatory response. Furthermore, DE exposure decreased LOXL1 and LOXL4 mRNA and increased MMP‐3 , MMP‐7 , and MMP‐12 protein levels therefore altering ECM turnover potential corroborated with STRING analysis. Cumulatively, DE‐induced miR‐133b‐3p downregulation and CTGF alteration are associated with Hippo pathway dysregulation, increased inflammation, and MMP/LOX ‐driven ECM remodeling in mouse lungs.
Inorganic arsenic, a naturally occurring metalloid found in groundwater, is a well-established human carcinogen. Epidemiological studies from highly contaminated regions link chronic arsenic exposure to increased risks of skin, lung, bladder, and kidney cancer. However, studies investigating the mechanisms driving arsenic-related mutagenicity in human tumors remain limited. To improve our understanding, we analyzed whole-exome sequencing (WES) data from tumor samples of 17 cancer patients treated in Dhaka, Bangladesh, with known or suspected exposure based on toenail arsenic concentrations. These patients included bladder (n = 9), kidney (n = 6), and lung (n = 2) cancers. The mutational burden (mutations per megabase) across all exomes ranged from 23 to 117 for single-base substitutions (SBS) and 2 to 13 for small insertions and deletions (indel). We showed that SBS and indel signatures, including SBS5, SBS6, ID6, and ID19 contributed the highest mutation load across all exomes. However, we did not observe associations between arsenic exposure levels and any mutational signature. We additionally analyzed WES data from two cell line models of chronic arsenic exposure, HaCaT skin epithelial and BEAS-2B lung epithelial cells exposed to low-dose of arsenite (100 nM) for 28 weeks. Consistent with the patient-derived results, we observed no exposure-related mutational burden or signature. Taken together, our findings suggest that arsenic alone may have limited independent mutagenic effects and instead may act through co-carcinogenic mechanisms. However, limited sensitivity to detect low-frequency mutations and small sample sizes potentially reduced our ability to capture mutational processes that may be associated with chronic arsenic exposure.